This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giles, F. J. Articles by Kantarjian, H. M. Search for Related Content PubMed PubMed Citation Articles by Giles, F. J. Articles by Kantarjian, H. M.

Phase I and Pharmacokinetic Study of DX-8951f (Exatecan Mesylate), a Hexacyclic Camptothecin, on a Daily-Times-Five Schedule in Patients with Advanced Leukemia¹

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, 77030 Texas [F. J. G.], and Daiichi Pharmaceutical Corporation, Montvale, New Jersey 07645

Purpose: DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity and myelosuppression as a dose-limiting toxicity in solid tumor Phase I studies. DX-8951f is active in a human acute myeloid leukemia (AML) severe combined immunodeficient mouse model. In a leukemia Phase I study, we investigated the toxicity profile and pharmacokinetics of DX-8951f in patients with primary refractory or relapsed AML or acute lymphocytic leukemia, myelodysplastic syndromes, or chronic myelogenous leukemia in blastic phase (CML-BP).

Experimental Design: DX-8951f was given as an i.v. infusion over 30 min daily for 5 or 7 days. The starting dose was 0.6 mg/m²/day for 5 days (3.0 mg/m²/course). Courses were given every 3–4 weeks according to toxicity and antileukemic efficacy.

Results: Twenty-five patients (AML, 21 patients; myelodysplastic syndrome, 1 patient; acute lymphocytic leukemia, 2 patients; CML-BP, 1 patient) were treated. Stomatitis was the dose-limiting toxicity, occurring in two of two patients treated at 1.35 mg/m²/day for 5 days, two of three treated at 1.2 mg/m²/day for 5 days, and one of six treated at 0.9 mg/m²/day for 7 days. The recommended Phase II dose was 0.9 mg/m²/day for 5 days. The pharmacokinetics of DX-8951 was linear and well fit by a two-compartment model.

Conclusions: Phase II studies are warranted to further define the activity of DX-8951f in patients with hematological malignancies.

This article has been cited by other articles:

				O. Soepenberg, M. J. A. de Jonge, A. Sparreboom, P. de Bruin, F. A. L. M. Eskens, G. de Heus, J. Wanders, P. Cheverton, M. P. Ducharme, and J. Verweij Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors Clin. Cancer Res., January 15, 2005; 11(2): 703 - 711. [Abstract] [Full Text] [PDF]

				T. Tonini, C. Gabellini, L. Bagella, G. D'Andrilli, V. Masciullo, G. Romano, G. Scambia, G. Zupi, and A. Giordano pRb2/p130 Decreases Sensitivity to Apoptosis Induced by Camptothecin and Doxorubicin but not by Taxol Clin. Cancer Res., December 1, 2004; 10(23): 8085 - 8093. [Abstract] [Full Text] [PDF]

				F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian Acute Myeloid Leukemia Hematology, January 1, 2002; 2002(1): 73 - 110. [Abstract] [Full Text]